US FDA Approves Anti-Epileptic Drug For Kids

Fycompa is now cleared for use in patients four years of age and older with partial-onset seizures.

US FDA Approves LENVIMA For Unresectable Liver Cancer

Lenvatinib mesylate was shown to improve overall survival in patients with unresectable liver cancer.

Eisai Joins Access Accelerated To Tackle Non-Communicable Diseases

Eisai will participate in a global partnership of pharmaceutical companies to help accelerate access to health care in low and middle-income countries.

Eisai & Keio University To Pursue Innovation In Dementia Drugs

The collaboration taps on Keio University's strengths in iPS technology and supercentenarian research.

Eisai Acquires Chinese Generics Company Liaoning TianYi

The acquisition of Liaoning gives Eisai a foothold in China's generics sector which accounts for 80 percent of the country's pharmaceutical market.

Removing Early Barriers To Drugs For Neglected Diseases

DNDi has formed a consortium with four pharmaceutical companies to hasten the development of drugs for leishmaniasis and Chagas disease.

Eisai To Make Clinical Trial Data Publicly Available

Requests for clinical trial data will be assessed by an independent review panel and the results released will be anonymized.

Eisai To Use Genomics’ Tools For Drug Discovery

The collaboration between Eisai and Genomics will focus on using genomic analyses to improve the drug development pipeline.

Eisai’s Thyroid Cancer Drug Gets US FDA Approval

A Phase III trial has shown that the drug Lenvima significantly improves the progression-free survival of thyroid cancer patients.

Eisai Deepens Its Presence In China

Japanese pharmaceutical Eisai has set up both a holding company and a new production facility in Suzhou, China.